Female Sexual Dysfunction (FSD) — CPB 0574 | AETNA Coverage Update

Aetna modified CPB 0574 covering Female Sexual Dysfunction (FSD), effective February 25, 2026. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its FSD coverage policy under CPB 0574 Aetna system to clarify what it considers experimental, investigational, or unproven. The policy now lists over 25 treatments — spanning codes like 0232T (platelet-rich plasma), 0672T (endovaginal radiofrequency remodeling), 64566 (percutaneous tibial nerve stimulation), and J0585–J0588 (botulinum toxin injections) — as non-covered for FSD indications. If your practice bills any of these codes with ICD-10 diagnoses in the F52 or N94 ranges, this update affects your reimbursement directly.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Female Sexual Dysfunction (FSD)
Policy Code	CPB 0574
Change Type	Modified
Effective Date	February 25, 2026
Impact Level	High
Specialties Affected	OB/GYN, urology, urogynecology, women's health, physical medicine
Key Action	Audit active charge capture for experimental codes and update claim documentation before billing FSD-related services

---

Aetna Female Sexual Dysfunction Coverage Criteria and Medical Necessity Requirements 2026

The Aetna FSD coverage policy under CPB 0574 takes a narrow view of what qualifies for reimbursement. Aetna does not define any specific treatment for FSD as medically necessary within this policy bulletin itself. Instead, the policy directs covered drug therapies — like Vyleesi (bremelanotide, billed via CPT 96372 for injection) and Osphena (ospemifene tablets) — to separate Pharmacy Clinical Policy Bulletins.

That's an important split. The medical necessity determination for drug-based FSD treatments lives in pharmacy policy, not CPB 0574. If your billing team is routing prior authorization requests for bremelanotide injections through the medical side, you're likely hitting the wrong channel.

For the treatments addressed directly in CPB 0574, Aetna's position is essentially a non-coverage stance. The bulletin is less a coverage policy in the traditional sense and more a formal exclusion list. Every intervention named gets classified as experimental, investigational, or unproven. There are no tiers, no prior auth pathways, and no criteria that unlock reimbursement for the listed codes.

Some Aetna plan designs also carry blanket exclusions for drugs or supplies used in sexual dysfunction treatment. Check benefit plan descriptions before billing — what the CPB 0574 Aetna policy says at the clinical level may not be the only barrier to payment.

---

Aetna Female Sexual Dysfunction Exclusions and Non-Covered Indications

This is where the policy has the most financial exposure for billing teams. Aetna explicitly classifies the following treatments as experimental, investigational, or unproven for FSD. That classification means claim denial is the expected outcome — not a risk.

The list is long. Botulinum toxin (J0585, J0586, J0587, J0588) is excluded. Platelet-rich plasma injections (0232T, P9020) are excluded. Platelet-rich fibrin injections are also excluded. Hyaluronic acid (J7318 through J7332) is excluded. Testosterone therapy via implant (CPT 11980, J1073) or injection (J1071, J1072, J3121, J3145) is excluded and cross-referenced to CPB 0528.

Laser and energy-based procedures face the same wall. Endo-vaginal and vulvar rejuvenation laser (CPT 17110, 17111) is excluded. Low-level laser therapy (0552T) is excluded. Radiofrequency ablation of the vaginal canal — including the MorpheusV applicator — is excluded. Radiofrequency thermal therapy, including ThermiVa and Viveve, is excluded. The endovaginal cryogen-cooled monopolar radiofrequency procedure billed under 0672T is also on the list.

Nerve stimulation approaches don't get coverage either. Percutaneous tibial nerve stimulation (CPT 64566) is excluded. Sacral neuromodulation is excluded. Transcranial direct current stimulation is excluded.

Drug-based interventions named in the bulletin as non-covered include oxytocin (J2590), progesterone (J2675), sildenafil (S0090), and phosphodiesterase type 5 inhibitors broadly — including tadalafil and vardenafil. Topical lidocaine is excluded. MDMA (methylenedioxymethamphetamine) is excluded, which reflects the investigational status of psychedelic-assisted therapy in women's health contexts.

Biothesiometry — a nerve conduction test used to diagnose FSD — is excluded for diagnostic use. That's a separate and notable point: Aetna won't cover the diagnostic workup with biothesiometry, not just the treatments.

Vibrators are specifically called out as non-covered durable medical equipment (DME). Aetna's position is that vibrators don't meet its contractual definition of covered DME because they have ordinary consumer use outside of illness or injury. Don't bill these expecting reimbursement.

Stem cell-based therapies, gene therapy, growth factor therapy, regenerative medicine, visnadine, and photobiomodulation of the vulvar region complete the exclusion list.

---

Coverage Indications at a Glance

---

Aetna Female Sexual Dysfunction Billing Guidelines and Action Items 2026

The effective date for this policy update is February 25, 2026. If your team hasn't audited active charge capture for FSD-related codes, do it now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Female Sexual Dysfunction Under CPB 0574

CPT Codes — Other Codes Related to This Policy

Code	Description Copy
11980	Subcutaneous hormone pellet implantation (estradiol and/or testosterone pellets)
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular

CPT Codes — Experimental / Not Covered for FSD

HCPCS Codes — Experimental / Not Covered for FSD

Key ICD-10-CM Diagnosis Codes

One note on the hyaluronic acid codes: all the J7318–J7332 codes normally describe intra-articular joint injections. Their inclusion in this FSD policy likely reflects off-label vaginal use of hyaluronic acid products. Don't assume these codes are universally non-covered — they may have valid reimbursement pathways for orthopedic indications. Flag them carefully in charge capture so the FSD-specific exclusion doesn't bleed into orthopedic claims by accident.

---